Gos­samer stops en­roll­ment on BTK in­hibitor pro­gram, goes all in on PAH drug

Gos­samer Bio is stop­ping en­roll­ment on a Phase Ib/II tri­al of its BTK in­hibitor in CNS lym­phoma, it said in its an­nu­al re­port Fri­day morn­ing.

The San Diego-based biotech said, “​​Based up­on the ben­e­fit / risk pro­file ob­served to date and a pri­or­i­ti­za­tion of re­sources to sup­port the ser­a­lu­tinib pro­gram,” it de­cid­ed to stop en­rolling the tri­al of the BTK in­hibitor known as GB5121. Next, Gos­samer plans to dis­cuss the avail­able da­ta with the tri­al’s da­ta re­view com­mit­tee, an in­de­pen­dent pan­el of ex­perts, to fig­ure out next steps. The tri­al orig­i­nal­ly ex­pect­ed to en­roll around 160 pa­tients, ac­cord­ing to a fed­er­al clin­i­cal tri­als data­base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER